Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
about
Hypomethylating agents for patients with myelodysplastic syndromeThrombopoietin mimetics for patients with myelodysplastic syndromesLow dose cytarabine monotherapy for myelodysplastic syndromesHypomethylating agents for patients with myelodysplastic syndromeSafety and efficacy of azacitidine in myelodysplastic syndromesTreatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.NaDirected therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.NaUse of azacitidine for myelodysplastic syndromes: controversial issues and practical recommendationsEpigenetic approaches in the treatment of myelodysplastic syndromes: clinical utility of azacitidineTargeting the epigenome in lung cancer: expanding approaches to epigenetic therapyA decade of exploring the cancer epigenome - biological and translational implicationsAn update on the safety and efficacy of decitabine in the treatment of myelodysplastic syndromesSafety and efficacy of azacitidine in the treatment of elderly patients with myelodysplastic syndromeHistone deacetylase inhibition in the treatment of acute myeloid leukemia: the effects of valproic acid on leukemic cells, and the clinical and experimental evidence for combining valproic acid with other antileukemic agentsA phase 2 study of vorinostat in acute myeloid leukemiaA clinical-molecular update on azanucleoside-based therapy for the treatment of hematologic cancersEpimutational profile of hematologic malignancies as attractive target for new epigenetic therapiesTargeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trialsDNA Methylation and Chromatin Remodeling: The Blueprint of Cancer EpigeneticsThe blind men and the AML elephant: can we feel the progress?Molecular and Cellular Mechanisms of Myelodysplastic Syndrome: Implications on Targeted TherapyHypoxia, Epithelial-Mesenchymal Transition, and TET-Mediated Epigenetic ChangesCharacterization of DNA Methylation in Circulating Tumor CellsSpotlight on decitabine for myelodysplastic syndromes in Chinese patientsTowards an understanding of the role of DNA methylation in rheumatoid arthritis: therapeutic and diagnostic implicationsThe complexity of epigenetic diseasesMyelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and managementMolecular Testing in Myelodysplastic Syndromes for the Practicing Oncologist: Will the Progress Fulfill the Promise?Targeting caspases in cancer therapeuticsBeyond hypomethylating agents failure in patients with myelodysplastic syndromesThe cancer epigenome: its origins, contributions to tumorigenesis, and translational implicationsNew ways to use DNA methyltransferase inhibitors for the treatment of myelodysplastic syndromeNew answers to old questions from genome-wide maps of DNA methylation in hematopoietic cellsInfections in myelodysplastic syndromesAllogeneic stem cell transplant for myelofibrosis patients over age 60: likely impact of the JAK2 inhibitorsEpigenetic regulators as promising therapeutic targets in acute myeloid leukemiaSome aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversyMyelodysplastic syndromes: what do hospitalists need to know?Clinical Results of Hypomethylating Agents in AML TreatmentA meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome
P2860
Q24186276-AEC65227-6518-4B8B-B2F4-BEAF505470D6Q24198060-CF2789B2-518D-4694-8EE3-10466F5C0D59Q24234789-B22CB241-F4BB-4E29-9F10-DADE49024731Q24236549-2B7FD6B8-6FAB-4CA8-95B8-B8C67D0ABE51Q24596561-EE878E34-A4B6-4AE4-BD82-3DB32A9C9337Q24597616-E01E508E-F8E8-4836-9E20-0C875D9053D5Q24599447-E3FC54F1-98B7-49EF-BB59-8BC0EE277669Q24605618-C59B3033-C002-4F76-8395-17FE74BFB8FCQ24608659-C8D5C256-8393-4BCE-9BBA-064E092F18DCQ24609974-E23C1A36-BE71-4BBA-91BA-016B0679FD82Q24614467-D7543938-9D4D-486B-9424-3009E05A0F9AQ24622700-5750B04F-AA85-4A3A-8FEB-AD60CFAB59D3Q24632949-7D651702-5A9F-43DE-AAAC-527B82FDC0E4Q24633763-BC0973EE-A2B6-42BD-A816-9A5B4C15C622Q24643266-469512E3-ADA2-45A1-A3BF-D72E296D3275Q26743743-AAE96CB4-7C18-401B-A0EE-0D3E8F37260EQ26744080-2F5ABCED-A754-4D79-A005-2C8AD0BA86BBQ26745731-F0628A5C-F13D-48A5-853D-F88F3CC33E1CQ26749421-B067A71E-A5D2-4A9D-8482-F4F8D11D6A12Q26749614-9DA3F70E-D1C4-459B-95C4-88267A2A9998Q26749870-B72D3E70-6BC6-460C-9D6F-62D75E57BF94Q26767183-AB16E563-79A0-4B86-BE4E-57BCBCD1823EQ26778427-9882257A-F6BB-4069-9D3E-773F92B56E38Q26778454-3D6DAFAD-4644-4CBA-AE2B-FF1B2B14A334Q26783490-42094DB1-59A9-4F93-B405-DFDA38AD03B9Q26784416-121C9556-8587-495B-9323-89E2DDF5E8E2Q26796240-AA242803-2D71-4DC2-BAEF-A0602577C6B5Q26801573-D0A17EF9-4B64-491E-82F1-A55A11FB772EQ26821986-B3B3CCFE-8CFE-4B62-95C4-B352C18F0909Q26827079-A2CD8894-5E97-4587-913F-A7AF36AF6EEBQ26828751-CE319A72-82B1-481A-B431-88535877BEB7Q26829132-907E9BF9-E09E-4506-A289-4961724BF671Q26851510-4039B92F-019C-4FF6-8EA5-7532509E316FQ26859275-F6156F29-FC50-45E3-B879-4A096909315CQ26863610-AA47AD4F-EE2A-4B57-B392-A538B6087094Q26865149-21BB12D9-6A71-490F-BE44-2C8D07375B71Q27010653-546CC99B-0BA1-4E75-915A-0BFE380F1DF4Q27011372-53ABD534-88EC-40DB-B6E4-A0A390A92A3BQ27022725-877E0FB6-28ED-442D-B878-A499FB8C5349Q27024786-05A364E4-8FBD-40F6-9266-21AA4212FC50
P2860
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
name
Efficacy of azacitidine compar ...... d, open-label, phase III study
@ast
Efficacy of azacitidine compar ...... d, open-label, phase III study
@en
Efficacy of azacitidine compar ...... d, open-label, phase III study
@nl
type
label
Efficacy of azacitidine compar ...... d, open-label, phase III study
@ast
Efficacy of azacitidine compar ...... d, open-label, phase III study
@en
Efficacy of azacitidine compar ...... d, open-label, phase III study
@nl
prefLabel
Efficacy of azacitidine compar ...... d, open-label, phase III study
@ast
Efficacy of azacitidine compar ...... d, open-label, phase III study
@en
Efficacy of azacitidine compar ...... d, open-label, phase III study
@nl
P2093
P2860
P50
P3181
P1433
P1476
Efficacy of azacitidine compar ...... d, open-label, phase III study
@en
P2093
Carlo Finelli
David McKenzie
Eva Hellstrom-Lindberg
Ghulam J Mufti
Jay Backstrom
John F Seymour
John M Bennett
Lewis R Silverman
Linda Zimmerman
P2860
P304
P3181
P356
10.1016/S1470-2045(09)70003-8
P407
P50
P577
2009-03-01T00:00:00Z